Almost a third of people treated with the higher dose had a bodyweight reduction of more than 25%, and 83.4% of patients with prediabetes at the start of the trial had returned to normal blood sugar levels by the end of the trial, compared to 73.8% for the standard dose and 36.6% for the placebo group
It is where safety is established
Although the primary focus of our study was on patients with overweight or obesity, approximately 29% of the cohort also had T2D, a significant subgroup due to the well-established link between T2D, psychiatric disorders, and obesity
As Daniell continued to share about her other health issues in connection with the weight gain, Jennifer had a hunch that our services at Viva could help
This personalization transforms treatment from guesswork into precision medicine, maximizing the likelihood that your first-chosen therapy actually works